Publications by authors named "Luke Barker"

Claim this Profile
B
Bridging the gap in trauma care across New Zealand.
Luke Barker, Ruth Duncan, James McKay, Christopher Wakeman

N Z Med J· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of a 3% Kānuka oil cream for the treatment of moderate-to-severe eczema: A single blind randomised vehicle-controlled trial.
Nicholas Shortt, Alexander Martin, Kyley Kerse, Gabrielle Shortt, Iva Vakalalabure, Luke Barker

EClinicalMedicine· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination immunotherapy including OncoVEX creates a favorable tumor immune micro-environment in transgenic BRAF murine melanoma.
Robyn D Gartrell, Zoë Blake, Emanuelle M Rizk, Rolando Perez-Lorenzo, Stuart P Weisberg, Luke Barker

Cancer Immunol Immunother· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Emergency department impact following the introduction of an electric scooter sharing service.
Sierra Beck, Luke Barker, Annie Chan, Signe Stanbridge

Emerg Med Australas· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FLT-PET At 6 Weeks Predicts Response Assessed by CT at 12 Weeks in Melanoma Patients Treated With Pembrolizumab.
Randy Yeh, Megan H Trager, Emanuelle M Rizk, Grace G Finkel, Luke W Barker

Clin Nucl Med· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Linking Transcriptomic and Imaging Data Defines Features of a Favorable Tumor Immune Microenvironment and Identifies a Combination Biomarker for Primary Melanoma.
Robyn D Gartrell-Corrado, Andrew X Chen, Emanuelle M Rizk, Douglas K Marks, Margaret H Bogardus, Luke W Barker

Cancer Res· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics.
Romain-David Seban, John S Nemer, Aurélien Marabelle, Randy Yeh, Eric Deutsch, Luke Barker

Eur J Nucl Med Mol Imaging· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II-III Melanoma.
Robyn D Gartrell, Douglas K Marks, Emanuelle M Rizk, Margaret Bogardus, Camille L Gérard, Luke W Barker

Clin Cancer Res· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic and Predictive Immunohistochemistry-Based Biomarkers in Cancer and Immunotherapy.
Emanuelle M Rizk, Robyn D Gartrell, Luke W Barker, Camden L Esancy, Grace G Finkel

Hematol Oncol Clin North Am· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of Tumor Antigen AF20 as Glycosylated Transferrin Receptor 1 in Complex with Heat Shock Protein 90 and/or Transporting ATPase.
Jason M Shapiro, Waihong Chung, Kosuke Ogawa, Luke Barker, Rolf Carlson

PLoS One· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unusual Features of Sodium Taurocholate Cotransporting Polypeptide as a Hepatitis B Virus Receptor.
Jisu Li, Li Zong, Camille Sureau, Luke Barker, Jack R Wands

J Virol· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral delivery and gastrointestinal absorption of soluble glucans stimulate increased resistance to infectious challenge.
Peter J Rice, Elizabeth L Adams, Tammy Ozment-Skelton, Andres J Gonzalez, Matthew P Goldman, Luke A Barker

J Pharmacol Exp Ther· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of fungal (1-3)-beta-D-glucans following intravenous administration in rats.
Peter J Rice, Brent E Lockhart, Luke A Barker, Elizabeth L Adams, Harry E Ensley

Int Immunopharmacol· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis